8-K: Tandem Diabetes Care Reports Strong Q4 and Full Year 2024 Results, Provides 2025 Guidance

Tandem Diabetes Care announces record sales for Q4 and full year 2024, driven by strong growth in pump shipments and expansion in the U.S. market, while also providing financial guidance for 2025.

Summary

• Tandem Diabetes Care reported its financial results for the fourth quarter and full year ended December 31, 2024, and provided financial guidance for the year ending December 31, 2025.
• Worldwide GAAP sales grew 44% to $282.6 million in Q4 2024 compared to Q4 2023.
• Worldwide non-GAAP sales grew 21% to $252.4 million in Q4 2024.
• Worldwide pump shipments increased by more than 25% in Q4 2024.
• For the full year 2024, worldwide GAAP sales grew 26% to $940.2 million, and worldwide non-GAAP sales grew 18% to $910.0 million.
• The company demonstrated a return to positive free cash flow in 2024.
• Tandem received FDA clearance for Control-IQ+ to include people living with type 2 diabetes.
• The company successfully launched a multi-channel durable medical equipment and pharmacy strategy for Tandem Mobi in the United States.
• Tandem signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology.
• For the year ending December 31, 2025, the company estimates sales to be approximately $997 million to $1.007 billion.
• Sales in the United States are estimated to be approximately $725 million to $730 million, and sales outside the United States are estimated to be approximately $272 million to $277 million.
• Gross margin is estimated to be approximately 54% for the full year 2025.
• Adjusted EBITDA margin is estimated to be approximately 3% for the full year 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong sales growth, FDA clearance, and strategic initiatives. While there are some losses reported, the overall tone is optimistic due to the projected growth and profitability in 2025.

Positives

• Record sales were achieved in Q4 and full year 2024.
• Worldwide pump shipments increased significantly.
• The company grew the United States insulin pump market by achieving a double-digit increase in people converting from multiple daily injections.
• Tandem Mobi pump shipments increased quarter-over-quarter throughout 2024.
• The company demonstrated a return to positive free cash flow.
• FDA clearance was received for Control-IQ+ to include people living with type 2 diabetes.
• A multi-channel durable medical equipment and pharmacy strategy for Tandem Mobi was successfully launched in the United States.
• A multi-year collaboration agreement was signed with the University of Virginia Center for Diabetes Technology.

Negatives

• Non-GAAP operating loss was $30.2 million in Q4 2024, compared to $22.5 million in Q4 2023.
• Adjusted EBITDA was $2.3 million in Q4 2024, compared to $4.3 million in Q4 2023.
• Non-GAAP operating loss totaled $128.1 million for the full year 2024, compared to $112.6 million for the full year 2023.
• Adjusted EBITDA was negative $10.1 million for the full year 2024, compared to negative $9.2 million for the full year 2023.
• Sales outside the United States reflect a $15 million to $20 million headwind associated with the company's preparation for direct commercial operations in select countries.

Risks

• The company's ability to achieve projected financial results will be impacted by market acceptance of its products.
• Products marketed and sold or under development by competitors could impact results.
• The company's ability to establish and sustain operations to support international sales, including expanding into additional geographies, is a risk.
• Changes in reimbursement rates or insurance coverage for the company's products could impact results.
• The company's ability to meet increasing operational and infrastructure requirements from higher customer interest and a larger base of existing customers is a risk.
• The company's ability to successfully commercialize its products is a risk.
• The company's ability to develop and launch new products is a risk.
• Risks are associated with the regulatory approval process outside the United States for new products.
• Newer products, or other technological breakthroughs for the monitoring, treatment or prevention of diabetes, may render the company's products obsolete or less desirable.
• Reliance on third-party relationships, such as outsourcing and supplier arrangements, is a risk.
• Global economic conditions could impact results.

Future Outlook

The company expects sales for the full year 2025 to be approximately $997 million to $1.007 billion, with a gross margin of approximately 54% and an adjusted EBITDA margin of approximately 3%.

Management Comments

• '2024 was a pivotal year for Tandem, as we returned to strong sales growth both in and outside of the United States, while delivering industry-leading customer satisfaction,' said John Sheridan, president and chief executive officer.
• 'We are continuing to transform our business in 2025 through the recent expansion of our U.S. sales force, commencing pharmacy coverage, and adding new features and indications to our robust portfolio as we work to improve the lives of people with diabetes,' said John Sheridan, president and chief executive officer.
• 'We are committed to delivering sustained profitable growth and are funding key commercial investments while driving operating leverage,' said Leigh Vosseller, executive vice president and chief financial officer.
• 'These investments focus on our U.S. sales infrastructure, business systems and technology, as well as the establishment of operations to support a direct launch in select European countries and are fundamental to achieving our longer-term financial objectives,' said Leigh Vosseller, executive vice president and chief financial officer.

Industry Context

Tandem's focus on innovation, such as the Control-IQ+ system and the Tandem Mobi pump, positions it well in the competitive diabetes technology market. The collaboration with the University of Virginia Center for Diabetes Technology further strengthens its position in developing advanced closed-loop insulin delivery systems. The expansion into pharmacy channels and direct commercial operations in select European countries reflects a strategic effort to broaden market access and improve customer reach.

Comparison to Industry Standards

• Tandem's growth in pump shipments and sales indicates a strong competitive position compared to other insulin pump manufacturers like Medtronic and Insulet.
• The adjusted EBITDA margin guidance of 3% for 2025 suggests a focus on profitability, which is a key metric for investors in the medical device industry.
• The company's investment in research and development, as evidenced by the collaboration with the University of Virginia, aligns with industry trends towards advanced diabetes management solutions.
• The expansion into pharmacy channels mirrors similar strategies employed by competitors to improve accessibility and affordability of insulin pump therapy.

Stakeholder Impact

• Shareholders can expect potential value appreciation due to the company's growth and profitability initiatives.
• Employees may benefit from the company's expansion and investment in its infrastructure.
• Customers will have access to new and improved products, such as the Control-IQ+ system and Tandem Mobi pump.
• Healthcare providers will have access to advanced diabetes management solutions to improve patient outcomes.

Next Steps

• Continue to expand the U.S. sales force.
• Commence pharmacy coverage.
• Add new features and indications to the portfolio.
• Establish operations to support a direct launch in select European countries.

Key Dates